| Project/Area Number |
25860779
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 巨核球前駆細胞 / 巨核球分化経路 / 純粋巨核球前駆細胞 / 巨核球 / 巨核球分化 |
|---|
| Outline of Final Research Achievements |
CD42b was expressed on some of common myeloid progenitors (CMP). This CD42b(+) CMP population could differentiate into only megakaryocyte lineage, which indicated this population was unipotent megakaryocte progenitor (MkP). CD42b(+)CMP was differentiated from CD41(+) subpopulation in Lineage(-)Sca1(+)Kit(+) cells (LSK). In single cell polymerase chain reaction analyses, the MkP and a fraction of CD41(+)LSK showed the similarities in mRNA expression profile, and were different from conventional bipotent megakaryocyte-erythroid progenitors (MEP).
On increased demand of platelet production after 5-FU treatment, a part of CD41(+)LSK population expressed CD42b on the surface, they showed skewed unipotent megakaryopoietic capacity. These results suggest that the CD41(+)LSK-MkP pathway is a novel, independent pathway of conventional CMP-MEP pathway, and may play physiologic roles especially in emergency megakaryopoiesis.
|
